Skip to content

Latest News

23/09/22

Spotlight on Dr Karl Roberts, Chief Operating Officer

In the latest instalment of George Medicines’ Spotlight interview series, Chief Operating Officer, Karl Roberts, tells us what drew him to George Medicines and how the company’s pipeline, alongside its partnership approach with other healthcare companies and organisations, has the potential to change the treatment paradigm for people living with non-communicable diseases, wherever they live …

15/09/22

Medisanté and George Medicines bring Internet of Things (IoT) data collection to decentralised Phase III trial

Remote cellular-enabled blood pressure monitoring provides novel and secure way of collecting real world data (RWD) in decentralised global phase III pivotal study. Unique remote device monitoring (RDM) capabilities of Medisanté’s medical IoT platform (M+ Hub) enhance George Medicines’ clinical trial management system. Seamless decentralised data collection of blood pressure measurements over a secure private …

07/09/22

George Medicines provides single-pill triple combination candidate for hypertension to VERONICA-Nigeria trial

Novel proprietary low-dose, single-pill triple combination, GMRx2, is in late-stage development with global Phase III trials underway Single-pill triple combination outperformed standard treatments without additional adverse effects in earlier clinical research VERONICA-Nigeria trial aims for more than 80% blood pressure control while improving cost-effectiveness in treating hypertension, providing a potential valuable tool to address the …

20/07/22

Triple combination candidate GMRx4 advances into Phase II clinical development for first-line treatment of type 2 diabetes

GMRx4 is the second candidate to be prioritised in Company’s pipeline of proprietary fixed-dose combination therapies targeting non-communicable diseases George Medicines receives $1.5 million investment from Australia’s national biotechnology incubator CUREator London, UK, 20 July 2022 – George Medicines, a late-stage drug development company focused on providing innovative and accessible medicines for the world’s leading …

25/05/22

In conversation with Professor Neil Poulter on May Measurement Month

Raised blood pressure is the number one cause of preventable death worldwide, and more than half of people who are hypertensive don’t know they have the condition. Over a billion people worldwide have hypertension, with most (two-thirds) living in low- and middle-income countries. Fewer than one in five people with hypertension have the problem under …

09/05/22

Spotlight on Stefan König, Chief Executive Officer

In the first of George Medicines’ Spotlight series of interviews, Chief Executive Officer, Stefan König, discusses his career, what led him to join George Medicines and how the Company is aiming to address the huge unmet need in hypertension treatment Can you tell us about your career before joining George Medicines? What motivated and inspired …